Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Media Release

SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,684,654) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent Office.

This United States patent was filed as a second divisional application and follows the grant of the United States parent patent and first divisional patent announced in December 2020 and March 2021, respectively.

The claims of the new patent build on the protection provided by the two previously granted patents, and are directed to methods of treating cancer by administering Immutep‘s lead active immunotherapy candidate eftilagimod alpha (“efti”) and a PD-1 pathway inhibitor, specifically BMS-936559, durvalumab, atezolizumab or avelumab. The expiry date of the patent is 15 November 2036 (including 312 days of patent term adjustment).

“We continue to build our patent estate around lead candidate efti, which is a unique biomolecule and shows great promise in being able to ultimately help diverse sets of cancer patients, including those with more complex needs. Here we add another key US patent which is closely aligned with our clinical development pipeline. These key patents support ongoing investment and allow us to confidently push forward across all of our business functions, including clinical, manufacturing, and business development,” said Marc Voigt, CEO of Immutep.

A continuation application and a further divisional application have been filed to pursue other embodiments of the invention.

About Eftilagimod Alpha (Efti)

Efti is Immutep’s proprietary soluble LAG-3 clinical stage candidate that is a first-in-class antigen presenting cell (APC) activator that stimulates both innate and adaptive immunity for the treatment of cancer. Efti binds to and activates antigen-presenting cells via MHC II molecules leading to expansion and proliferation of CD8+ (cytotoxic) T cells, CD4+ (helper) T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like IFN-ƴ and CXCL10 that further boost the immune system’s ability to fight cancer.

Efti is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with anti-PD-[L]1 immunotherapy and/or chemotherapy.

Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA).

About Immutep

Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to market for patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Investors/Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com

 

Staff

Recent Posts

CoVet Expands Clinical Leadership with Launch of In-House Medical Department

Veterinary AI leader CoVet introduces a dedicated Medical Department to ensure clinical accuracy, real-world relevance,…

5 hours ago

New ASTHO Legal Map Illuminates State and Territorial Suicide Prevention Infrastructure

ARLINGTON, Va., July 24, 2025 /PRNewswire/ -- The Association of State and Territorial Health Officials…

5 hours ago

Loomis expands its Pharma business by acquiring Kipfer-Logistik

STOCKHOLM, Sweden, July 24, 2025 /PRNewswire/ -- Loomis AB has, through its subsidiary Loomis International…

5 hours ago

HealthArc and PatchRx Partner to Boost Medication Adherence in Pain Management

Integrated RTM solution to deliver real-time medication adherence insights for pain and mental health practices.…

5 hours ago

Loopback Analytics Welcomes Industry Leader Elizabeth Cherry as Vice President of Access Solutions

DALLAS, July 24, 2025 /PRNewswire/ -- Loopback Analytics is excited to welcome Elizabeth Cherry, PharmD,…

5 hours ago

123Invent Inventor Develops Modified Glasses to Assist with Reading (BRA-8028)

PITTSBURGH , July 24, 2025 /PRNewswire/ -- "I wanted to create reading glasses like to no…

5 hours ago